Analyst Research

Report Title Price
Provider : Reuters Investment Profile
Provider : Stock Traders Daily
Provider : New Constructs, LLC
Provider : S&P Capital IQ – STARS Reports

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Sanofi teams up with UCB for research in immune-mediated diseases

Tuesday, 11 Mar 2014 02:01am EDT 

Sanofi SA:Enters into strategic collaboration with UCB for discovery and development of anti-inflammatory small molecules to treat wide range of immune-mediated diseases in areas such as gastroenterology and arthritis.Costs and profits shared 50/50.UCB entitled to initial upfront, preclinical and clinical development milestone payments from Sanofi, potentially above 100 million euros. 

Company Quote

1.53 +2.27%
12 Feb 2016